A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TRALOKINUMAB IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN CHILDREN (AGE 2 TO <12 YEARS) AND INFANTS (AGE 6 MONTHS TO <2 YEARS) WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.

Intervention/treatment:
ADTRALZA
Medical condition:
ATOPIC DERMATITIS
Protocol code:
LP0162-1336
Control number:
284137
Status:
Recruiting
Approved:
March 21, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06311682
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
6 Months to 11 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Disclosure
Role
CONTACT
Phone:
+45 4494 5888
Sponsor
LEO PHARMA INC

Locations

Leo Pharma Investigational site
Burlington, L7L 6W6
RECRUITING
Leo Pharma Investigational site
Calgary, Calgary
WITHDRAWN
Leo Pharma Investigational site
Calgary, T2J 7E1
RECRUITING
Leo Pharma Investigational site
Edmonton, T5J 3S9
RECRUITING
Leo Pharma Investigational site
Edmonton, T6G 1C3
RECRUITING
Leo Pharma Investigational site
Hamilton, L8S 1G5
RECRUITING
Leo Pharma Investigational site
Niagara Falls, L2H 1H5
RECRUITING
Leo Pharma Investigational site
Saskatoon, S7K 2C1
RECRUITING
Leo Pharma Investigational site
Windsor, N8X2G1
RECRUITING
Leo Pharma Investigational site
Winnipeg, R3M 3Z4
RECRUITING
Did you find what you were looking for?